Cresset, founded in 2001 and headquartered in the United Kingdom, is at the forefront of revolutionizing molecule design through its integration of cutting-edge science with AI/ML. The company focuses on enhancing cross-team communication and accelerating the DMTA cycle with its innovative software solutions.
With its slogan, "Software, expertise and collaborative solutions to advance insights across the DMTA cycle", Cresset provides sophisticated tools for chemists in leading research organizations, enabling faster and more efficient discovery and optimization of small molecules. Their comprehensive offerings include patented CADD Software, the collaborative Torx® DMTA platform, and access to expert Discovery CRO scientists.
Cresset is strategically positioned in industries such as pharmaceuticals, agrochemicals, and flavors and fragrances. The company received its last venture round investment from Scottish Equity Partners on 21 September 2022, highlighting a strong ongoing interest from investors.